CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...